Mercury Laboratories Share Price | Mercury Laboratories Stock Screener
MERCURYLAB
Pharmaceuticals
Share Price BSE
₹840.00
▼
-10.70 (-1.26%)
As of June 22, 2026, the Mercury Laboratories share price (BSE: MERCURYLAB) is ₹840.00, down 1.26% from the previous close, with shares trading between ₹839.95 and ₹855.70, and a 52-week range of ₹700.00–₹904.00.
Check MERCURYLAB 52-week performance for the annual price range and momentum.
Use the Mercury Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Mercury Laboratories Market Cap
₹93.00 Cr.
MERCURYLAB P/E Ratio (TTM)
19.24
Mercury Laboratories P/B Ratio
1.60
EPS (TTM)
₹40.28
Dividend Yield
0.45%
Debt to Equity
0.11
MERCURYLAB 52 Week High
₹904.00
Mercury Laboratories 52 Week Low
₹700.00
Operating Margin
11.00%
Profit Margin
6.58%
MERCURYLAB Revenue (TTM)
₹76.00
EBITDA
₹9.00
Net Income
₹5.00
Total Assets
₹79.00
Total Equity
₹58.00
Mercury Laboratories Share Price Chart
Screen Mercury Laboratories share price with an interactive chart. Analyse MERCURYLAB price trends and volatility across different timeframes.
Mercury Laboratories Company Profile - Fundamental Screener
Screen Mercury Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MERCURYLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE947G01011
Mercury Laboratories Balance Sheet Screener
Screen MERCURYLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 79 | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 |
| Current Assets | 45 | 40 | 40 | 40 | 35 | 38 | 32 | 32 | 30 | 32 |
| Fixed Assets | 34 | 25 | 24 | 24 | 26 | 26 | 24 | 24 | 21 | 18 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 9 | 6 | 5 | 4 | 6 | 10 | 9 | 11 | 12 | 10 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 58 | 54 | 51 | 46 | 40 | 37 | 32 | 29 | 26 | 25 |
| Share Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves & Surplus | 57 | 52 | 50 | 44 | 39 | 36 | 31 | 28 | 25 | 23 |
Mercury Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Mercury Laboratories income statement and profit fundamentals.
Analyze MERCURYLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Mercury Laboratories share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76 | 76 | 77 | 77 | 59 | 70 | 58 | 57 | 52 | 48 | 48 | 42 |
| Expenses | 67 | 68 | 67 | 67 | 51 | 59 | 51 | 50 | 48 | 41 | 41 | 35 |
| EBITDA | 9 | 8 | 10 | 10 | 8 | 11 | 7 | 7 | 5 | 7 | 7 | 7 |
| Operating Profit % | 11.00% | 9.00% | 12.00% | 11.00% | 12.00% | 14.00% | 11.00% | 10.00% | 9.00% | 14.00% | 14.00% | 14.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 7 | 5 | 7 | 7 | 5 | 8 | 4 | 4 | 3 | 5 | 5 | 5 |
| Tax | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 1 | 1 |
| Net Profit | 5 | 3 | 6 | 6 | 4 | 5 | 3 | 3 | 2 | 3 | 4 | 3 |
| EPS | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 | 16.78 | 22.53 | 32.69 | 27.61 |
Mercury Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen MERCURYLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 4 | 8 | 3 | 5 | 8 | 6 | 5 | 5 | 2 | 0 |
| Investing Activities | -9 | -6 | -1 | -2 | -5 | -1 | -5 | -4 | -2 | 0 |
| Financing Activities | -1 | -1 | -1 | -1 | -1 | -3 | -3 | 1 | 0 | 1 |
| Net Cash Flow | -6 | 1 | 0 | 2 | 2 | 1 | -2 | 2 | 0 | 0 |
Mercury Laboratories Shareholding Pattern Screener
See Mercury Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Mercury Laboratories promoter holding and ownership changes for MERCURYLAB on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.58% | 16.66% | 16.66% | 16.71% | 16.59% | 16.86% | 16.86% | 16.79% |
| Other Holding | 9.77% | 9.68% | 9.68% | 9.63% | 9.76% | 9.48% | 9.48% | 9.55% |
| Shareholder Count | 1,316 | 1,397 | 1,384 | 1,365 | 1,321 | 1,214 | 1,259 | 1,345 |
Mercury Laboratories Share Dividend Screener - Share Yield Analysis
Check Mercury Laboratories dividend history with payout and yield data.
View Mercury Laboratories dividend details including ex-dates and amounts for MERCURYLAB stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹3.50 | 0.50% |
| 2024-March | ₹3.50 | 0.43% |
| 2023-March | ₹3.50 | 0.42% |
| 2022-March | ₹3.50 | 0.63% |
| 2021-March | ₹3.50 | 0.72% |
| 2020-March | ₹2.00 | 0.31% |
| 2019-March | ₹1.50 | 0.53% |
| 2018-March | ₹1.50 | 0.44% |
| 2017-March | ₹1.50 | 0.38% |
Mercury Laboratories Stock Index Membership
See which indices include Mercury Laboratories stock.
Check MERCURYLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Mercury Laboratories Market Events Screener - Corporate Actions
Get Mercury Laboratories corporate actions including splits, bonuses, and buybacks.
Check Mercury Laboratories stock events that may affect MERCURYLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -1.49% | ||
| Annual General Meeting | NA | -1.04% | ||
| Dividend | ₹ 2.00 /share | -10.51% | ||
| Dividend | ₹ 3.50 /share | 24.21% | ||
| Dividend | ₹ 3.50 /share | 25.90% | ||
| Dividend | ₹ 3.50 /share | 19.51% | ||
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.61% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 2.06% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 2.38% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | -4.77% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -6.45% |
| 2025-08-06 | 2025-08-06 | Dividend | ₹ 3.50 /share | -0.90% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -1.75% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -4.38% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.88% |
Mercury Laboratories Competitors Screener - Peer Comparison
Screen MERCURYLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 433,248 | 37.66 | 58,220 | 6.38% | 11,565 | 50.53 |
| Divis Laboratories | 175,621 | 68.32 | 10,560 | 8.73% | 2,520 | 48.68 |
| Torrent Pharmaceuticals | 152,757 | 71.37 | 13,886 | 20.34% | 2,138 | 56.10 |
| Cipla | 112,112 | 28.90 | 29,045 | 2.24% | 3,870 | 52.20 |
| Zydus Life Science | 109,197 | 21.36 | 26,720 | 13.65% | 5,242 | 63.58 |
| Dr Reddys Laboratories | 107,185 | 25.68 | 33,593 | -0.44% | 3,998 | 47.29 |
| Lupin | 103,854 | 19.41 | 27,488 | 19.98% | 5,345 | 49.08 |
| Mankind Pharma | 98,726 | 50.73 | 14,278 | 12.03% | 1,750 | 51.82 |
| Aurobindo Pharma | 81,608 | 23.33 | 33,385 | 3.21% | 3,376 | 40.75 |
| Laurus Labs | 74,970 | 84.30 | 6,868 | 22.01% | 890 | 60.94 |
Mercury Laboratories Company Announcements - News Screener
Screen MERCURYLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Corrigendum To Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-29 | Book Closure Intimation For AGM | - |
| 2026-05-29 | Corporate Action-Board approves Dividend | - |
| 2026-05-29 | Audited Financial Results For The Year Ended On March 31 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Outocme Of Board Meeting Held On May 29 2025 | - |
| 2026-05-28 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-23 | Board Meeting Intimation for Approval Of Audited Financial Results Of The Company For The Quarter And Year Ended On March 31 2026 Together With The Draft Directors Report. | - |
| 2026-05-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-07 | Intimation To Shareholders Relating To Transfer Of Equity Shares To IEPF Authority | - |
| 2026-04-29 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-29 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-29 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Results- Financial Results As On December 31 2025 | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On 11.02.2026 | - |